Financial reports
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
2 Mar 22
10-Q
2021 Q3
Quarterly report
3 Nov 21
Current reports
8-K
Entry into a Material Definitive Agreement
8 Nov 23
8-K
Entry into a Material Definitive Agreement
26 Sep 23
8-K
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
2 Aug 23
8-K
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
23 Jun 23
8-K
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
22 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
25 May 23
8-K
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
19 May 23
8-K
Entry into a Material Definitive Agreement
17 May 23
8-K
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
27 Apr 23
8-K
Entry into a Material Definitive Agreement
24 Mar 23
Registration and prospectus
15-12G
Securities registration termination
20 Nov 23
POS AM
Prospectus update (post-effective amendment)
8 Nov 23
POS AM
Prospectus update (post-effective amendment)
8 Nov 23
POS AM
Prospectus update (post-effective amendment)
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Nov 23
Proxies
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
20 May 22
DEFA14A
Additional proxy soliciting materials
13 May 22
DEF 14A
Definitive proxy
2 May 22
DEF 14A
Definitive proxy
27 Apr 21
PRE 14A
Preliminary proxy
15 Apr 21
DEF 14A
Definitive proxy
29 Apr 20
PRE 14A
Preliminary proxy
15 Apr 20
DEF 14A
Definitive proxy
30 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
Other
EFFECT
Notice of effectiveness
15 Nov 23
EFFECT
Notice of effectiveness
15 Nov 23
EFFECT
Notice of effectiveness
15 Nov 23
CT ORDER
Confidential treatment order
5 May 21
CT ORDER
Confidential treatment order
4 Dec 20
CT ORDER
Confidential treatment order
1 Oct 18
CT ORDER
Confidential treatment order
21 Aug 18
CT ORDER
Confidential treatment order
20 Jun 18
CT ORDER
Confidential treatment order
11 Apr 18
UPLOAD
Letter from SEC
14 Feb 18